Discontinuation of antimalarial drugs in systemic lupus erythematosus

Journal of Rheumatology

Volumn 26, Issue 4, 1999, Pages 808-815

  Wang, Chenchen ^b   Fortin, Paul R ^b   Li, Yin ^b   Panaritis, Tina ^b   Gans, Mark ^b   Esdaile, John M ^a  

^a Mary Pack Arthritis Centre   (Canada)

^b NONE

Author keywords

Antimalarial; Discontinuation; Myopathy; Retinopathy; Side Effect; Systemic Lupus Erythematosus

Indexed keywords

ANTIMALARIAL AGENT; HYDROXYCHLOROQUINE;

ADULT; ARTICLE; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HEADACHE; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTIGO; VISUAL DISORDER;

ADULT; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; COHORT STUDIES; DRUG TOXICITY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LIFE TABLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MUSCULAR DISEASES; RETINAL DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 0032915109     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of anti-malarials in systemic lupus erythematosus. J Rheumatol 1975; 2:323-30.
2. Lockshin MD. Therapy for systemic lupus erythematosus [editorial]. N Engl J Med 1991;324:189-91.
3. The Canadian Hydroxychloroquine Study Group. A randomized trial of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med 1991:324:150-4.
4. The Canadian Hydroxychloroquine Study Group. A randomized longterm study of hydroxychloroquine withdrawal on major exacerbations in SLE [abstract]. Arthritis Rheum 1995;38 Suppl:S347.
5. Galindo M, Rodriguez M, Criado B, de la Cruz J, Ciruelo E, Mateo I. Protective effect of antimalarial drugs in systemic lupus erythematosus [abstract]. Arthritis Rheum 1996;39 Suppl:S255.
6. Meinão IM, Sato EI, Andrade LEC, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996:5:237-41.
7. Williams HJ, Egger MJ, Singer JZ, et al. Comparison' of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21:1457-62.
8. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am J Med 1995;98:156-68.
9. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1993;119:1067-71.
10. Richter JA, Runge LA, Finals RS, Oates RP. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol 1980;7:153-9.
11. Husain Z, Runge LA. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole. J Rheumatol 1980;7:825-30.
12. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987;16:206-21.
13. Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med 1983;75 Suppl:52-6.
14. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity trade-offs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
15. Flato B, Vinje O, Forre O. The toxicity of antirheumatic medications in children [abstract]. Arthritis Rheum 1996;39 Suppl:S236.
16. Goldsmith DP, Chalom EC, Urban MA, et al. Lack of toxicity of hydroxychloroquine in a regional cohort of children with rheumatic disorders [abstract]. Arthritis Rheum 1996;39 Suppl:S236.
17. Harris ED Jr. Hydroxychloroquine is safe and probably useful in rheumatoid arthritis [editorial]. Ann Intern Med 1993;119:1146-7.
18. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
19. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
20. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
21. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993;20:645-9.
22. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
23. Anon. Drugs for rheumatoid arthritis. Medical Letter 1997:5-15.
24. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
25. Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
26. Morand EF, McCloud PI, Littlejohn GO, Continuation of longterm treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992;51:1318-21.
27. Anderson RJ. Hydroxychloroquine therapy in rheumatic diseases. Bull Rheum Dis 1996;44:6-8.
28. Klinkhoff AV, Beattie CW, Chalmers A. Retinopathy in systemic lupus erythematosus: relationship to disease activity. Arthritis Rheum 1986;29:1152-6.
29. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy: patterns, associations, and prognosis. Arthritis Rheum 1988:31:1105-10.
30. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Petersen T. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 1997; 40:1482-6.
31. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 1990:4:572-6.
32. MacLean CH, Lee PP, Keeler EB. Cost analysis of routine ophthalmologic screening for hydroxychloroquine retinal toxicity [abstract]. Arthritis Rheum 1996; 39 Suppl:S72.
33. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
34. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
35. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6.
36. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DB. The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993:20:661-5.
37. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994:96:254-9.
38. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993;2 Suppl 1:S13-S15.
39. Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity: clinical and pathologic perspective. Am J Med 1987;82:447-55.
40. Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 1995:34:166-70.
41. Seguin P. Camus C, Leroy J-P, Le Tulzo Y, Jouannic I, Thomas R. Respiratory failure associated with hydroxychloroquine neuromyopathy. Eur Neurol 1995:35:236-7.
42. Easterbrook M. Dose relationships in patients with early chloroquine retinopathy. J Rheumatol 1987;14:472-5.
43. Rynes RI, Krohel G, Falbo A, Reinecke RD, Wolfe B, Bartholomew LE. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum 1979;22:832-6.
44. Bellamy N, Brooks PM. Current practice in antimalarial drug prescribing in rheumatoid arthritis. J Rheumatol 1986;13:551-5.
45. Finbloom DS, Silver K, Newsome DA. Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-4.
46. Avina-Zubieta A, Galindo-Rodriquez G, Grieve C, Suarez-Almazor ME, Russell AS. Long-term effectiveness of antimalarials in rheumatic diseases [abstract]. Arthritis Rheum 1996;39 Suppl:S208.
47. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292-6.
48. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J 1992;85:274-9.
49. Spalton DJ, Roe GMV, Hughes GRV. Hydroxychloroquine, dosage parameters and retinopathy. Lupus 1993;2:355-8.
50. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991; 112:528-34.
51. Easterbrook M, Bernstein H. Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. J Rheumatol 1997:24:1390-2.
52. Koehler B, Beattie C, Beaudet F, et al. Antimalarial workshop. J Rheumatol 1997;24:1393-5.
53. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.
54. Corzillius M, Bienfang D, Liang MH. Cost-effectiveness analysis of screening for hydroxychloroquine-induced retinopathy. [abstract]. Arthritis Rheum 1997;40 Suppl:S316.
55. Block JA. Hydroxychloroquine and retinal safety [editorial]. Lancet 1998;351:771.
56. Anon. Hydroxychloroquine sulfate (Plaquenil). Can Med Assoc J 1998:158:943.
57. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in longterm hydroxychloroquine treatment. Ann Rheum Dis 1996:55:187-9.
58. Sfikakis PP, Rougas K, Papazoglou S, Charalambopolous D, Mavrikakis M. Irreversible retinal toxicity in longterm hydroxychloroquine treatment [abstract]. Arthritis Rheum 1997;40 Suppl:S58.
59. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992;27:237-9.
60. Ehrenfeld M, Nesher R, Merin S. Delayed-onset chloroquine retinopathy. Br J Ophthalmol 1986;70:281-3.